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A B S T R A C T
Summary recent studies have provided novel evidence regarding the effect of nicotine agonists on the prevention
or modulation of cytokines storm and reduction of infection. In this study we tried to attempt to address these
issues from a therapeutic perspective of nicotine agonists in this manner and we describe one of the most
challenging theories of immunotherapy in coronavirus-19 (COVID-19). The analysis of the proposed mechanism
goes beyond the physiological consequences of a way to design new strategies to provide anti-inflammatory
drugs.
Introduction
Coronaviruses appear periodically and unpredictably from year
2002 with the onset of SARS-COV, and then with MERS-COV and now
with COVID-19 (SARS-CoV-2). This family of viruses causing infectious
diseases and they became a constant threat to human health. There is
no definitive and approved treatment for cardiorespiratory sequels of
these COV infections. Although from a pathophysiological point of view
there is a deep understanding of the immune response to the virus,
there is no approved treatment for immunomodulation in these patients
thus it seems that treatment of immune system problems such as sys-
temic pulmonary inflammatory responses associated with COV is ne-
cessitating. Immunity based treatment can be a good alternative and
savior therapy to some antiviral treatment. As we know cytokine storms
in lung tissue in most deadly events in patients with COV infection.
Therefore, in cases of COV induced pneumonia, it is important to
control cytokine production and inflammatory response. Although this
strategy is challenging due to a lack of clear immune response and
endangering the host defense, it does not seem impossible. In an at-
tempt to address these issues from a therapeutic perspective, we de-
scribe our hypothesis about one of the most challenging theories of
immunotherapy in COV viruses.
Hypothesis
Replication of RNA viruses such as the COV family is accompanied
by excessive production of interferons, neutrophils and macrophages
which brings about a massive immune response, referred to as “cyto-
kine storm”. This overproduction negatively affects the balance of the
inflammatory responses and the normal function of cytokines.
This immune system disorder can lead to series of symptoms in-
cluding fever, edema, and hypotension in mild cases. In severe cases it
can cause systemic inflammation, heart failure, pulmonary failure
which consequently led acute respiratory syndrome and eventually
death. In COVID-19 infection, like other coronavirus infections, a si-
milar scenario is expected with varying degrees of immune inter-
ference.
It is expected that the management of the activity and performance
of the cytokines might lead to the prevention of severe endothelial
dysfunctions and pulmonary fibrosis in patients affected by COVID-19.
Previous studies have demonstrated the indicated impressive relation
between the nervous system and immune system. These studies de-
monstrated that nervous system has modulatory effects on the pro-
duction of multiple inflammatory cytokines in lung tissue [1,2].
The cholinergic pathway, via acetylcholine neurotransmitters, can
interact with nicotinic acetylcholine receptors. Further activation of
these receptors can apply a suppressive effect on the production of pro-
inflammatory cytokines [3] (Fig. 1). Among the nicotine receptor sub-
types, the subunit 7(α-7) is the most prominent due to its high ex-
pression in immune cells (B cells, macrophages, T cells, and target cells)
and its association with humoral and intrinsic immunity. Therefore,
evaluation of pharmacological approaches to activate α-7nAChR for
inhibition of immunologic phenomenon such as cytokine storm can be
helpful. Nicotine is a non-selective agonist of this receptor that mimics
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acetylcholine binding to stimulate vagal activity and decrease cytokine
function and block the inflammatory pathway. The general algorithm of
this idea was illustrated in Fig. 2. Hence, comprehension of this theory
can provide better therapeutic guidance for the treatment of cor-
onavirus infections, especially COVID-19.
Discussion
We describe one of the trends in the decline of the cytokine storm. It
seems that lethality and uncontrolled complications of coronaviruses
are due to the lack of control of the cytokine storms. Although the
pathogenesis of coronaviruses is complex and requires specific treat-
ment, previous studies have shown the efficacy of neutralizing anti-
inflammatory cytokines in inflammatory conditions caused by COVID-
19 [1]. Dose-dependent anti-inflammatory effects of the 7nAChR-1
agonist have been demonstrated, and previous studies have shown that
activation of this receptor can have an anti-inflammatory role and
immune cells regulating [4]. Nicotine is agonist of mentioned receptor
but cannot be used clinically due to its toxicity, addictive nature, and
lack of specificity. Other agonists of 7nAChR-1 receptors in this group,
such as GTS-21, produce the same nicotine effects without nicotine
problems. Also some studies have reported limited use of GTS-21 in the
clinical phase and have shown that this agent can cause a decrease of
cytokine levels and significantly reduced inflammatory biomarker after
infection [3,5]. It has been thought that a nicotine agonist compound
like GTS-21 is able to suppress the production of pro-inflammatory
Fig. 1. The hypothetical cellular ‘COVID-19 inflammatory pathway” virus with the influx of neutrophils and monocytes/macrophages results in the hyperproduction
of pro-inflammatory cytokines. And “cytokine storm” occurs, weakened by the intensification of the immune system's inflammatory response. But it seems that
‘nicotinic anti-inflammatory pathway’ triggered by the α7 nAChR in immune cells during infection, bacterial components, or intracellular mediators trigger pro-
inflammatory pathways that converge in the activation of the NF-kB, which will translocate into the nucleus and induce the transcriptional activation of a variety of
inflammatory cytokines. Nicotine inhibits the production of pro-inflammatory cytokines in macrophages by mechanism dependent on the α7nAChR.
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cytokines during infection of COVID-19. In fact, these nicotine agonists
can control allergic inflammation induced by innate immune and cel-
lular immune pathways. Taken together according to mentioned lit-
erature review it can be concluded that GTS-21, as potent 7nAChR-1
receptor agonist, will act as an anti-inflammatory agent against COVID-
19- infection-induced cytokine storm and inflammatory disturbances in
respiratory system and reduced the risk of death in infected subjects.
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Fig. 2. Schematic design of the virus-induced inflammatory pathway which
probably block by the nicotine agonist.
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